What's in Oman Medical Speciality Board's pipeline?

Oman Medical Speciality Board has 5 drugs in our index: 1 marketed, 0 filed, 2 in Phase 3, 1 in Phase 2, 1 in Phase 1.

Which companies overlap with Oman Medical Speciality Board's portfolio?

Top competitors by shared drug class: Seoul National University Hospital, American University of Beirut Medical Center, AstraZeneca, Amphastar Pharmaceuticals, Inc., Antibe Therapeutics Inc..

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/oman-medical-speciality-board.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-16 · How we verify

Oman Medical Speciality Board — Portfolio Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Oman Medical Speciality Board pipeline: 1 marketed, 0 filed, 2 Phase 3, 1 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

1 marketed 0 filed 2 Phase 3 1 Phase 2 1 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area
nebulized epinephrine	nebulized epinephrine	marketed	Sympathomimetic amine / Adrenergic agonist	Alpha-1 and beta-2 adrenergic receptors	Pulmonology / Emergency Medicine
Placabo	Placabo	phase 3			Other
Intravenous Diltiazem	Intravenous Diltiazem	phase 3	Non-dihydropyridine calcium channel blocker	L-type voltage-gated calcium channel	Cardiovascular

Therapeutic area mix

Cardiovascular · 1
Other · 1
Pain Management · 1
Pulmonology / Emergency Medicine · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Seoul National University Hospital · 2 shared drug classes
American University of Beirut Medical Center · 1 shared drug class
AstraZeneca · 1 shared drug class
Amphastar Pharmaceuticals, Inc. · 1 shared drug class
Antibe Therapeutics Inc. · 1 shared drug class
Apsen Farmaceutica S.A. · 1 shared drug class
Amneal Pharmaceuticals, LLC · 1 shared drug class
Allergan · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Oman Medical Speciality Board:

Cite this brief

Drug Landscape (2026). Oman Medical Speciality Board — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/oman-medical-speciality-board. Accessed 2026-05-16.